Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-Guided Copanlisib, Bendamustine, and Rituximab in CLL/SLL
NCT04155840Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Jan 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of copanlisib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by University of Washington. Started Jan 2020; status: terminated.
02
Drugs
copanlisib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04155840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155840.